Abstract:Background: Imatinib, a frontline targeted-therapeutic agent for patients with chronic myelogenous leukemia (CML), was a synthetic tyrosine kinase inhibitor approved by the US Food and Drug Administration. Objective: To expand the structural diversity of Bcr-Abl inhibitors, we synthesized nine novel imatinib analogues (1a-1i) and evaluated their cytostatic effects against human cancer cell lines in vitro. Method: Imatinib and its analogues were successfully synthesized by an improved method in six main steps. Inhibitory activities of all compounds were evaluated on K562, HL-60, MCF-7, A549 and PBMC in vitro. Then, the effect of the most active compound was studied using flow cytometer, real-time qPCR and western blot experiments to determine its mechanism action. Finally, the molecular docking of the most active compound were determined. Results: The IC50 of one imatinib analogue (compound 1h) for K562 and HL-60 was lower than imatinib itself. Further studies indicate that the pro-apoptotic effect of compound 1h on K562 cells was stronger than imatinib over a range of concentrations. Importantly, the real-time qPCR and western blot experiments showed that compound 1h was superior to imatinib in inhibiting Bcr-Abl expression. The structure-activity relationship was analyzed by determining the inhibitory rate of each imatinib analogue. Introducing benzene (A ring) and piperidine (E ring) rings instead of pyridine (A ring) and piperazine (E ring) in imatinib significantly enhanced the potency of imatinib against K562 and HL-60 cell lines, which is consistent with the docking results. Conclusion: Imatinib analogue 1h showed a better inhibitory effect on leukemia cell lines than other cell lines, which was consistent with the imatinib-like structure, moreover, had little effect on PBMC. Overall, we conclude that compound 1h has the potential to treat chronic myeloid leukemia.

Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl T315I inhibitor overcoming acquired imatinib resistance.

Identification of Gzd824 As an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance Against Imatinib

Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl) benzamide derivatives as potent pan Bcr-Abl inhibitors including the threonine315←isoleucine315 mutant

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)

Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1h-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) As a Highly Potent ABL Kinase Inhibitor Capable of Overcoming a Variety of ABL Mutants Including T315I for Chronic Myeloid Leukemia

Recent Advances In Bcr-Abl Tyrosine Kinase Inhibitors For Overriding T315i Mutation

The Novel Anticancer Agent JNJ-26854165 is Active in Chronic Myeloid Leukemic Cells with Unmutated BCR/ABL and T315I Mutant BCR/ABL Through Promoting Proteosomal Degradation of BCR/ABL Proteins

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors

Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia

Bcr-Abl Inhibitory Activities of Imatinib Derivatives

Allosteric inhibitors of Bcr-abl–dependent cell proliferation

Design, Synthesis, and Biological Evaluation of Bcr-Abl PROTACs to Overcome T315I Mutation

Abstract 1980: S116836 Overcomes BCR-ABL T315I Mutation Mediated Imatinib Resistance in Chronic Myeloid Leukemia

Discovery of a Candidate Containing an (S)-3,3-difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1h-inden Scaffold As a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia.

Hybrid Pyrimidine Alkynyls Inhibit The Clinically Resistance Related Bcr-Abl(T315i) Mutant

In silico identification of novel kinase inhibitors targeting wild-type and T315I mutant ABL1 from FDA-approved drugs

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

Recent Developments In The Third Generation Inhibitors Of Bcr-Abl For Overriding T315i Mutation

Identification of Bisindolylmaleimide IX As a Potential Agent to Treat Drug-Resistant BCR-ABL Positive Leukemia

Design, Synthesis, and Biological Evaluation of Novel Bcr-AblT315I Inhibitors Incorporating Amino Acids As Flexible Linker

Design, Synthesis, and Biological Evaluation of Trizole-Based Heteroaromatic Derivatives As Bcr-Abl Kinase Inhibitors.